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Discontinuation of anti-VEGF cancer therapy
promotes metastasis through a liver
revascularization mechanism
Yunlong Yang1,2,*, Yin Zhang2,*, Hideki Iwamoto2, Kayoko Hosaka2, Takahiro Seki2, Patrik Andersson2,
Sharon Lim2, Carina Fischer2, Masaki Nakamura2, Mitsuhiko Abe2, Renhai Cao2, Peter Vilhelm Skov3, Fang
Chen4, Xiaoyun Chen5, Yongtian Lu1, Guohui Nie1 & Yihai Cao2,6
The impact of discontinuation of anti-VEGF cancer therapy in promoting cancer metastasis is
unknown. Here we show discontinuation of anti-VEGF treatment creates a time-window of
profound structural changes of liver sinusoidal vasculatures, exhibiting hyper-permeability
and enlarged open-pore sizes of the fenestrated endothelium and loss of VE-cadherin.
The drug cessation caused highly leaky hepatic vasculatures permit tumour cell intravasation
and extravasation. Discontinuation of an anti-VEGF antibody-based drug and sunitinib
markedly promotes liver metastasis. Mechanistically, host hepatocyte, but not tumour
cell-derived vascular endothelial growth factor (VEGF), is responsible for cancer metastasis.
Deletion of hepatocyte VEGF markedly ablates the ‘off-drug’-induced metastasis. These
ﬁndings provide mechanistic insights on anti-VEGF cessation-induced metastasis and raise a
new challenge for uninterrupted and sustained antiangiogenic therapy for treatment of
human cancers.
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A
nti-VEGF-based antiangiogenic drugs including
bevacizumab, aﬂibercept, ramucirumab and tyrosine
kinase inhibitors (TKIs) targeting vascular endothelial
growth factors (VEGFRs) are routinely used for treatment of
various human cancers1–9. In general, survival improvement by
addition of an antiangiogenic component to conventional
chemotherapeutics is modest2,3,10–12. For example, multiple
lines of clinical trials have shown that treatment of colorectal
cancer (CRC) patients with bevacizumab only produced very
limited beneﬁcial effects4,13–18. At this time of writing, it is still
unclear about the fundamental mechanism by which these anti-
VEGF drugs in combination of chemotherapy produce clinical
beneﬁts. Moreover, most rigorous clinical trials demonstrate that
anti-VEGF monotherapy rarely improves overall survivals of
patients with most cancer types4,6–12. The lack of sufﬁcient
clinical beneﬁts of anti-VEGF drugs in human cancer patients has
raised several unresolved issues including: the mode of action,
selection of responsive patient populations, treatment timeline
and drug resistance mechanisms. Based on a series of preclinical
and clinical studies, many speculative hypotheses and concepts
have been put forward to explain these unresolved clinical issues.
It is generally believed that blocking the VEGF-VEGFR signalling
would augment compensatory mechanisms of tumour
angiogenesis by elevating expression levels of angiogenic factors
that these drugs do not target, circumventing the VEGF-
dependent angiogenic signals2,19–22. Another hypothesis claims
that anti-VEGF drugs normalize tumour vasculatures and blood
perfusion, and alleviate tumour hypoxia, leading to improved
delivery of chemotherapeutics in combination therapeutic
settings23. For intrinsic non-responders, it is speculated that
tumours employ non-VEGF proangiogenic factors to grow
vessels. However, these hypotheses warrant further clinical
validation.
VEGF (also called VEGF-A) is the prototype of a family of
angiogenic factors and it modulates angiogenesis, vascular
remodelling, vascular permeability and multiple non-vascular
functions24–26. For high-afﬁnity binding receptors, endothelial
VEGFR2 transduces angiogenic and vascular permeability
signals, whereas VEGFR1 might commit to some non-vascular
functions or serve as a decoy signalling system27,28. Almost all
human tumour tissues express high levels of VEGF relative to
their healthy tissue counterparts29. Thus, various drugs targeting
the VEGF-VEGFR signalling pathway have been developed for
treatment of human cancer patients. Intervention at almost every
step of the VEGF signalling pathway has been considered for drug
development. For example, bevacizumab neutralizes VEGF,
ramucirumab binds to VEGFR2 and blocks its interaction with
VEGF, aﬂibercept traps VEGF ligands, TKIs block activation of
VEGFRs, and everolimus, temsirolimus and zotarolimus inhibit
the downstream mechanistic target of rapamycin functions24. In
addition to clinical beneﬁts, the antiangiogenic therapy-altered
tumour microenvironment has been cautioned for promoting
metastasis in experimental mouse models30,31.
Despite the fact that original designs of these drugs are
targeting the tumour vasculature, during clinical practice,
anti-VEGF drugs are systemically delivered to cancer patients.
To date, no available antiangiogenic drugs are speciﬁcally
delivered to the tumour local microenvironment. Systemic
administration of anti-VEGF agents would indistinguishably
cause global drug exposure to all tissues and organs. Recent
studies from our laboratory and others show that systemic
delivery of anti-VEGF drugs produces broad effects on regression
of healthy vasculatures in various organs32,33. In addition, there
has been lacking a uniﬁed opinion on timeline of antiangiogenic
therapy. In theory, non-stop treatment with anti-VEGF drugs
should be given to cancer patients as VEGF continues to be
functional after discontinuation of treatment. However, during
clinical practice, interrupted anti-VEGF regimens are used in
cancer patients because of drug-related adverse effects, economic
reasons or drug resistance. It is unclear if withdrawal of
antiangiogenic therapy would produce harmful effects that
may jeopardize patient survivals. This important issue has not
been fully explored although discontinuation of VEGF treatment
is routinely undertaken during clinical practice. In particular, the
‘off-drug’-associated vascular changes of non-tumour healthy
vasculatures in various tissues and organs in promoting cancer
metastasis are completely unknown.
In the present work, we have studied discontinuation of
anti-VEGF therapy-altered healthy hepatic vasculatures in
facilitating cancer metastasis. In several mouse tumour
models, we have validated the concept that the anti-VEGF
cessation-associated regrowth and remodelling of hepatic
vasculatures provide a structural basis of cancer metastasis.
Mechanistically, the host hepatocyte- but not tumour cell-derived
VEGF is responsible for facilitating cancer metastasis. Based on
these ﬁndings, non-stop persistent anti-VEGF therapy is
recommended for treatment of human cancer patients and
cautions should be paid during drug holidays.
Results
Liver vascular changes by on- and off-anti-VEGF therapy. Liver
metastasis is commonly seen in patients with various cancers.
In particular, CRC often metastasizes to liver and bevacizumab in
combination with chemotherapeutics is given as the ﬁrst-line
option for treatment of CRC patients4. To study the impact of
anti-VEGF treatment on hepatic vasculature, a rabbit anti-mouse
VEGF neutralizing antibody (VEGF blockade)32,34–37 was used
for treatment of tumour-free healthy mice (Supplementary
Fig. 1a). After receiving VEGF blockade for 7 days, marked
regression of hepatic vasculatures was observed (Fig. 1a).
Discontinuation of VEGF blockade resulted in a rapid
revascularization of hepatic vasculatures despite the long
half-life of VEGF blockade36. By day 12, hepatic vessels
recovered to the non-treated level (Fig. 1a). During recovery
angiogenesis, hepatic vasculatures did not exhibit obvious
disorganization and were functionally perfused (Fig. 1a and
Supplementary Fig. 1b). Hepatic vasculatures exhibited positivity
of ﬁbronectin and collagen IV, two principal components
of the extracellular matrix and basement membrane around
hepatic microvessels (Supplementary Fig. 1c). VEGF blockade
had no effects on ﬁbronectin and collagen IV expression.
Notably, cessation of VEGF blockade-induced revascularization
occurred along the trails of the basement membrane
sleeves (Supplementary Fig. 1c). Hepatic microvessels lacked
laminin and NG2þ pericytes, except the central arterial vessel
(Supplementary Fig. 1d).
Without VEGF blockade treatment, healthy liver tissue
experienced very modest hypoxia as measured by CA9 levels
and VEGF blockade augmented severe tissue hypoxia even after
cessation of treatment for 18 days (Fig. 1b). Consistently, HIF-1a
expression levels were elevated during VEGF blockade treatment
(Fig. 1c). Consistent with elevated hypoxia and HIF-1a
expression levels, liver VEGF mRNA and the non-antibody-
bound free VEGF protein levels were also signiﬁcantly
increased at day 6 after withdrawal of VEGF blockade (Fig. 1d
and Supplementary Fig. 1e). The mechanism underlying
hypoxia-induced increased Hif-1a mRNA level might be due to
increased stability of Hif-1a mRNA. Liver non-antibody-bound
free VEGF molecules were able to activate VEGFR2 by
stimulation of phosphorylation (Fig. 1e). The phosphorylated
VEGFR2 levels corresponded with the elevated levels of liver-free
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Figure 1 | Revascularization of liver microvasculatures after withdrawal of systemic anti-VEGF treatment. (a) Time-course analysis of CD31þ
microvessels in livers before anti-VEGF treatment, on-drug and off-drug. Scale bar, 50mm. Data were quantiﬁed from nine random ﬁelds per group. (b) Liver
tissue hypoxia measured by CA9 expression in various groups. Scale bar, 100mm. Data were quantiﬁed from nine random ﬁelds per group. (c) RT-PCR and
qPCR quantiﬁcation of Hif1a expression in various on- and off-drug groups (triplicates per group). (d) ELISA measurement of non-antibody-bound free VEGF in
different groups (triplicates per group). (e) Measurement and quantiﬁcation of total and phosphorylated VEGFR2 protein levels in various groups (triplicates
per group). (f) Measurements of extravasation of Fluorescein-labelled 70-kDa-dextran and expression levels of VE-cadherin in different groups. Arrows point
to leaked dextran signals. Scale bar in upper panel, 25mm. Scale bar in lower panel, 10mm. Data were quantiﬁed from nine random ﬁelds per group. OFF, off-
drug; ON, on-drug. (mean±s.e.m., NS, not signiﬁcant, Student’s t-test); Full gel images for e are shown in Supplementary Fig. 8.
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VEGF protein. Similar hepatic vascular changes in response to
on- and off-anti-VEGF therapy were also seen in tumour-bearing
mice (Supplementary Fig. 1f)
Time-course studies showed that revascularization of hepatic
vasculatures exhibited hyper-permeability of 70-kDa-dextran
between days 6 and 8 after cessation of VEGF blockade treatment
(Fig. 1f). Increases of vascular leakage persisted for at least 18
days after discontinuation of anti-VEGF treatment, albeit the
levels of leakiness were weakened relative to days 6 and 8 (Fig. 1f).
Reconciling with hyper-vascular leakiness, regenerated hepatic
vessels showed transient loss of VE-cadherin, an adhering protein
zipping endothelial cell tight junctions. After day 10 off-drug,
VE-cadherin expression levels recovered to the untreated
physiological level (Fig. 1f).
To further validate these ﬁndings, we used a clinically available
TKI, sunitinib, for treatment of tumour-free healthy mice. Sunitinib
treatment in principle reproduced similar results as the anti-VEGF
neutralizing antibody (Fig. 1 and Supplementary Figs 1–3). There
were few particular characteristics of sunitinib that distinguished
from the anti-VEGF antibody treatment. First, the off-drug-
triggered revascularization occurred much faster than VEGF
blockade. After only day 6 off-drug, revascularization of hepatic
vessels reached to the untreated physiological level (Supplementary
Fig. 2). The off-drug-triggered rapid revascularization likely
reﬂected the short half-life of sunitinib as a small molecule. The
second interesting feature was that liver VEGF protein level was
markedly elevated during sunitinib treatment, which persisted at
least until day 2 off-drug (Supplementary Fig. 2d). Despite the
elevated hepatic VEGF level at day 7 during treatment, VEGFR2 in
the liver tissue did not become signiﬁcantly phosphorylated
(Supplementary Fig. 2e). Robust VEGFR2 phosphorylation was
only detected at day 2 off-drug, indicating ineffectiveness of
sunitinib and the presence of high level of VEGF in the liver tissue
(Supplementary Fig. 2e). Third, increased vascular leakage was
found during sunitinib treatment, probably reﬂecting the short
half-life of this small molecule (Supplementary Fig. 2f).
Off-drug induces enlargement of pore sizes of liver vessels.
Under physiological condition, liver microvasculatures consist of
sinusoidal discontinuous capillaries that possess incomplete basal
membrane and fenestrated endothelial lining, manifesting
sinusoidal open pores on the vessel wall. The average size of
sinusoidal open pores in mouse liver was B75 nm in diameter
and anti-VEGF treatment did not signiﬁcantly alter fenestration
pore sizes (Fig. 2a,c). Cessation of anti-VEGF blockade and
sunitinib resulted in marked structural changes of liver sinusoidal
capillaries with marked enlargement of pore sizes. Sinusoidal pore
sizes of 15–20-fold increase were often observed after dis-
continuation of anti-VEGF treatments (Fig. 2a–d). For the VEGF
blockade-treated liver, pore enlargement occurred at day 6 off-
drug and persisted at least until day 28 after treatment (Fig. 2a,c
and Supplementary Fig. 4a). At day 42 off-drug, sinusoidal pore
sizes returned to those before treatment (Supplementary Fig. 4).
Compared with VEGF blockade, sunitinib-treated liver showed
early expansion of sinusoidal pore sizes already at day 2 off-drug
(Fig. 2b,d). However, enlarged pores reversed to normal sizes
already at day 21 off-drug (Supplementary Fig. 4b). Diameters of
some sinusoidal pores reached 1,000 nm (Supplementary
Fig. 4c). The off-sunitinib triggered early occurrence and termi-
nation of pore enlargement again reﬂected a short half-life
relative to the VEGF blockade. Of note, vascular cast imaging
analysis showed distinctive features of liver sinusoidal capillaries
after discontinuation of treatment. Both off-VEGF blockade and
off-sunitinib triggered bulb-like structures, reﬂecting highly
leakiness of liver sinusoidal capillaries (Fig. 2a,b,e,f).
Off-drug promotes metastasis by increasing extravasation.
Giving the fact that withdrawal of anti-VEGF therapy induced
hyper-leakiness and loss of VE-cadherin in hepatic capillaries,
we hypothesized that off-drug would increase tumour cell
extravasation in liver. To test this hypothesis, we chose a CRC
model for two main reasons. First, liver metastasis is commonly
seen in CRC patients14. Second, anti-VEGF treatment with
bevacizumab has been approved as the key component of the
ﬁrst-line therapy for treatment of CRC patients4. To study the
possible increase of CRC cell extravasation, green ﬂuorescent
protein (GFP)-and luciferase-labelled mouse MC38 CRC cells
were injected into the mouse spleen. This model recapitulated the
clinical situation of spontaneous metastasis (Fig. 3a).
Before tumour cell implantation, animals were pretreated with
VEGF blockade or sunitinib for 7 days. Of interest, marked
increases of tumour cell extravasation were detected after only
24 h tumour implantation at day 6 off-VEGF blockade and at day
2 off-sunitinib (Fig. 3b). It seemed that discontinuation of
sunitinib augmented a higher level of CRC cell extravasation
relative to the VEGF blockade (Fig. 3b). After 3-week tumour
implantation, discontinuation of anti-VEGF therapy augmented
marked increases of liver metastasis as compared with the group
receiving continuous anti-VEGF treatment (Fig. 3c,d). Notably,
both groups of mice receiving discontinuation of VEGF blockade
and sunitinib showed higher metastatic luciferase signals than
their corresponding non-treated groups (Fig. 3c,d). Gross
examination and histological analysis of liver tissues further
validated the presence of increased numbers and sizes of
metastatic nodules (Fig. 3e–h). We further investigated tumour
cell extravasation in livers after 18 days off-drug. Despite
complete recovery of liver microvessel density at this time point,
capillaries contained enlarged open pores and exhibited high
leakiness (Figs 1 and 2 and Supplementary Fig. 4). Therefore,
these structural features could be accessible for tumour cell
extravasation, which eventually led to increases of liver
metastasis. Indeed, implantation of MC38 CRC cells in spleen
at day 18 after cessation of anti-VEGF therapy resulted in
signiﬁcant increases of liver metastasis (Supplementary Fig. 5).
These ﬁndings demonstrate that discontinuation of anti-VEGF
therapy facilitates liver metastasis.
Tumour VEGF-independent mechanism of off-drug metastasis.
To exclude the possibility of tumour cell-derived VEGF in attri-
buting liver metastasis in our off-drug settings, we used VEGF-
null tumour cells that completely lacked the Vegf gene37,38.
Consistent with genetic deletion of the Vegf gene, VEGF-null
tumour cells completely lacked a detectable level of VEGF protein
(Supplementary Fig. 6a). In the spontaneous spleen metastasis
model, deletion of tumour cell VEGF did not prevent the
anti-VEGF cessation-triggered liver metastasis (Supplementary
Fig. 6b–e). Withdrawal of VEGF blockade and sunitinib resulted
in accelerated liver metastases, which were validated by
expression of luciferase expression and histological examination.
To further investigate tumour cell extravasation through
regenerated liver microvessels, we used an independent metastatic
model by injecting tumour cells into the portal vein. Similar to the
spleen model, withdrawal of VEGF blockade at day 6 and
sunitinib at day 2 resulted in signiﬁcant increases of liver
metastasis (Fig. 4a–h). It should be emphasized that the number
of metastatic nodules in off-VEGF blockade and off-sunitinib
groups were markedly higher than their corresponding controls,
reﬂecting the increases of extravasated tumour cells (Fig. 4a–h).
Again, deletion of the Vegf gene in tumour cells did not
signiﬁcantly affect the enhanced liver metastasis after cessation of
anti-VEGF therapy (Fig. 4a–h). Similar to the spontaneous spleen
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metastasis model, injection of tumour cells into the portal vein
markedly increased tumour cell extravasation at day 6 off-VEGF
blockade and at day 2 off-sunitinib (Fig. 4i). These results further
validated off-anti-VEGF therapy-induced extravasation in a
portal vein metastasis model. Thus, our results from two
independent models support the fact that discontinuation of
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Figure 2 | Scanning electron microscopic and vascular cast analyses of liver microvasculatures. (a,b) Representative scanning electron microscopy and
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Figure 3 | CRC tumour cell extravasation and metastasis in livers. (a) Schematic model of MC38 tumour cell implantation in spleen and liver metastasis
and treatment schemes. (b) Histological analysis of extravasation of GFPþ tumour cells in livers received on- and off-anti-VEGF therapy. Arrowheads point
to extravasated tumour cells. Scale bar in upper panel, 100mm. Scale bar in upper panel, 25mm. Data were quantiﬁed from nine random ﬁelds per group.
(c,d) Representative mouse pictures of various groups subjected to luminescent imaging analysis of luciferase activity in metastatic cancers. Red
arrowheads point to luciferase positivity. Data were quantiﬁed from 6 mice per group. (e,f). Representative liver micrographs subjected to luminescent
luciferase activity analysis (n¼6 animals per group). Red arrowheads point to luciferase positivity. H&E histological analysis of liver metastasis. Dashed
lines mark the borders between tumour and liver tissues. L, liver; T, tumour. Scale bar in lower panels, 25 mm. Quantiﬁcations of liver luciferase activity
(n¼6 animals per group). (g,h) Quantiﬁcations of visible surface liver metastatic nodules (n¼6 animals per group). OFF, off-drug; ON, on-drug.
(mean±s.e.m., Student’s t-test).
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anti-VEGF therapy promotes liver metastasis through a tumour
cell VEGF-independent mechanism.
Hepatocyte VEGF facilitates metastasis. To deﬁne the molecular
players attributing to the drug withdrawal-triggered liver
metastasis, we further studied the role of host VEGF in
promoting metastasis. Since VEGF is a key angiogenic factor in
maintaining the fenestrated vascular structures in different tissues
and organs, it is likely that the host-derived VEGF attributes to
metastasis. The fact that discontinuation of anti-VEGF treatment
increased expression levels of VEGF in the liver tissue
supports this notion (Fig. 1 and Supplementary Fig. 1). To
provide further experimental evidence, we took a genetic
approach to delete hepatocyte VEGF by delivery of an
adenovirus-Cre in Vegfﬂox/ﬂoxmice. This approach has previously
been shown to effectively delete VEGF expression in
hepatocytes39. Indeed, this conditional knockout approach
effectively reduced VEGF expression hepatocyte VEGF
(Fig. 5a). Along with reduction of hepatocyte VEGF levels,
drug-cessation-triggered liver metastasis of MC38 CRC was
signiﬁcantly inhibited in the spleen spontaneous metastasis model
(Fig. 5b–g). These ﬁndings demonstrate that hepatocyte-derived
host VEGF, but not tumour cell-derived VEGF is crucially
required for facilitating liver metastasis.
Off-drug promotes metastasis in a CRC orthotopic model. To
recapitulate the clinical situation of CRC metastasis, we
further developed an orthotopic model of cancer metastasis
by implanting CRC tumour cells in the caecum of the mouse
colon (Fig. 6a). CRC tumour cells were labelled with GFP for
monitoring metastasis. In this model, tumours were implanted to
caecum before receiving drug therapy. When tumours reached an
average size of B1.0 cm (ref. 3), tumour-bearing mice were
systemically treated with VEGF blockade and sunitinib
until tumour reached to B1.5 cm3. At day 6 after withdrawal
of VEGF blockade and at day 2 after withdrawal of sunitinib,
mice were killed for immunohistological examination of tumour
cell extravasation. At these time points, tumour angiogenesis
was signiﬁcantly inhibited (Supplementary Fig. 7a,b). In both
VEGF blockade and sunitinib off-drug groups, signiﬁcantly
increased extravasation of tumour cells were observed in liver
tissues (Fig. 6b,c). Therefore, discontinuation of antiangiogenic
therapy promotes cancer metastasis in an orthotopic primary
tumour model.
Off-drug promotes lung metastasis in a HCC orthotopic model.
In addition to increases of tumour cell extravasation,
discontinuation of anti-VEGF therapy-triggered hepatic
microvascular alterations could also potentially promote hepatic
cellular carcinoma (HCC) metastasis by a mechanism of
facilitating tumour cell intravasation. To test this possibility,
Hepa1-6 tumour cells were implanted into liver tissues at day 6
off-VEGF blockade and at day 2 off-sunitinib therapy. After 24 h
off-drugs, tumour cell intravasation in the same liver lobe,
but apart from the primary site, was subjected for immunohis-
tochemical analysis. Indeed, higher numbers of intravasated
tumour cells were present in off-antiangiogenic drug-treated
groups relative to their respective controls (Fig. 6d–f). Circulating
tumour cells were detected by culturing tumour cells in the
peripheral blood. Signiﬁcant increases of tumour cell colonies
were detected in groups receiving discontinuation of anti-VEGF
therapy (Fig. 6g,h). Tumour-bearing mice were killed B4 weeks
after tumour cell implantation and liver weight was not
signiﬁcantly different from the control group (Supplementary
Fig. 7c). However, signiﬁcant increases of metastatic nodules were
observed in lung tissues, suggesting increase of HCC intravasa-
tion in the liver microvasculature (Fig. 6i,j). Taken together, these
data show that discontinuation of anti-VEGF therapy promotes
HCC metastasis through a possible mechanism of enhancing
intravasation via hyper-permeable liver microvasculatures.
Discussion
Based on the antiangiogenic concept for cancer therapy,
antiangiogenic drugs should be sustainably delivered to cancer
patients as non-stop treatment. Discontinuation of antiangiogenic
therapy would cause rapid revascularization in tumours
and perhaps even a ‘rebound effect’ of tumour angiogenesis40.
One of the mechanisms underlying rapid revascularization is that
antiangiogenic treatment triggers tumour hypoxia, which induces
expression of hypoxia-regulated angiogenic factors such as VEGF
(ref. 41). In the present study, we have found that off-targets of
antiangiogenic therapy induce hypoxia and VEGF expression in
healthy tissues such as in the liver. Like endocrine organs in
the body, homeostasis of liver sinusoidal vasculatures is
maintained by VEGF (ref. 42). Systemic inhibition of VEGF
functions by drugs such as bevacizumab and sunitinib would
block the physiological functions of VEGF in the liver, leading to
marked regression of microvessels32,33. It seems that the
regeneration mechanism of these sinusoidal vasculatures on
cessation of treatment is also dependent on the availability of
VEGF. Our ﬁndings validate the previous notion that vascular
regeneration occurs along the regressive trail of the basement
membrane-constituted sleeves that retained expression of
collagen IV (ref. 33).
An interesting notion is that the off-drug-triggered liver
revascularization exhibited a transient hyper-leakiness and the
regenerated endothelium contains enlarged open-pores that were
not seen under physiological conditions. Some of these enlarged
open pores have sizes of B1 mm in diameters. Along with these
structural changes, expression of VE-cadherin, which is crucial
for maintenance of inter-endothelial cell tight junctions43,44
is also lost. Thus, hyper-vascular permeability is likely achieved
by enlargement of fenestrated open-pores in endothelium and
opening of inter-endothelial cell tight junctions. Would these
structural changes permit tumour cell intravasation and
extravasation? In different metastasis models, we show that
marked increases of tumour cell extravasation through the wall of
regenerated liver microvasculatures. Given the fact that some
open-pore sizes reach 1 mm in diameter and tumour cell possesses
the intrinsic features of spindle-like morphology, it is highly
plausible for tumour cells to transmigrate through these large
open pores. In particular, metastatic tumour cells undergo
epithelial-mesenchymal transition45, exhibiting highly elongated
spindle-like morphology that might potentially migrate through
the altered endothelium. Alternatively, a piggyback of tumour cell
transmigration mechanism with aides of inﬂammatory cells or
stromal ﬁbroblasts might also exist as these stromal cells are
known to facilitate cancer metastasis46–48. The loss of VE-
cadherin supports the opening of inter-endothelial cell junction
and transmigration of tumour cell through the vessel wall.
One of the surprising ﬁndings of our study is that
discontinuation of antiangiogenic therapy created a long-lasting
effect of sinusoidal vascular changes. In both bevacizumab- and
sunitinib-treated animals, after day 18 off-drug liver microvessel
numbers recovered to the pre-treated levels and were superﬁcially
normalized. However, the endothelium contains high numbers of
fenestrated open-pores and exhibits hyper-permeability.
Although off-anti-VEGF therapy produces long-lasting impacts
on liver vascular structures, discontinuation of VEGF blockade
seems to produce longer sinusoidal dilation than sunitinib. The
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disparity between anti-VEGF neutralizing antibody and sunitinib
perhaps reﬂects the difference of pharmacokinetics of these two
drugs. Even though the anti-VEGF antibody has a long half-life
that is equivalent to bevacizumab, withdrawal of the antibody
produced a rapid revascularization in the liver, which recovers to
the untreated level within 12 days. The antibody molecules are
still present in the body as antigen–antibody complexes that lack
ability for VEGF neutralization. Functional inactivation of anti-
VEGF antibody also supports the fact of existence of high levels of
biologically active VEGF in the tumour microenvironment after
cessation of anti-VEGF therapy. There are probably two
mechanisms involving in off-anti-VEGF therapy-triggered long-
lasting liver vascular changes. First, remodelling of vascular
fenestrations and perhaps tight junctions needs longer time than
growing new vessels. Second, induction of sinusoidal dilations
and other structural changes are likely more sensitive to VEGF
than angiogenesis. Slight increases of VEGF molecules after
cessation of anti-VEGF drugs are still able to maintain hyper-
permeability of liver sinusoidal vasculatures.
Prolonged hyper-leakiness of liver microvasculatures after
discontinuation of anti-VEGF therapy provides greater chances
for tumour cell intravasation and extravasation through the vessel
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Figure 6 | Extravasation and intravasation of tumour cells in orthotopic tumour models. (a) Schematic model of an orthotopic CRC metastasis model.
CRC primary tumours were implanted in the caecum for subsequent liver metastasis. (b,c) Extravasation of CRC tumour cells at 24 h after drug cessation
in various off-drug groups. Arrowheads point to extravasated tumour cells. Scale bar in upper panels, 100mm. Scale bar in lower panels, 25mm.
Quantiﬁcation of extravasated GFPþ tumour cells (n¼8 ﬁelds per group). (d) Schematic model of HCC tumour cell implantation in liver and lung
metastasis. (e,f) Intravasation of HCC tumour cells at 24 h after tumour cell implantation in various off-drug groups. Arrowheads point to extravasated
tumour cells. Scale bar in upper panels, 50mm. Scale bar in lower panels, 25 mm. Quantiﬁcation of intravasated GFPþ tumour cells (n¼ 8 ﬁelds per group).
(g,h) Representative circulating tumour cell colony pictures and quantiﬁcation of visible circulating tumour cell colonies (n¼6 animals per group).
(i,j) Representative lung pictures and quantiﬁcation of visible metastatic nodules (n¼6 animals per group). Red arrowheads point to visible metastatic
nodules. Immunohistological analysis of lung metastasis. Dashed lines mark the borders between tumour and lung tissues. T, tumour; Scale bar in upper
panels, 1 cm. Scale bar in lower panels, 50mm. OFF, off-drug; ON, on-drug. (mean±s.e.m., Student’s t-test).
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wall. Tumour cell extravasation through leaky liver microvessels
occurs within a relatively short time. After 24 h tumour cell
implantation, signiﬁcant numbers of circulating tumour cells
were extravasated in the liver tissue. This ﬁnding suggests that
persistent tumour cell extravasation occurs in the liver tissue after
discontinuation of antiangiogenic therapy. This is a clinically
important issue because a primary tumour continuously release
tumour cells into the circulation49. Circulating tumour cells
disseminated from the primary site would serve as an incessant
source for extravasation. In a clinically relevant orthotopic CRC
model in which spontaneous cancer metastasis occurs, we have
observed signiﬁcant increases of tumour cell extravasation in
livers after cessation of antiangiogenic therapy. Highly leaky liver
microvessels also facilitate intravasation of tumour cells in an
orthotopic HCC model.
During clinical practice with antiangiogenic cancer therapy, it is
almost inevitable for discontinuation of antiangiogenic therapy
owing to ineffectiveness, development of drug resistance, adverse
effects and economically unaffordable high costs. Decisions of
continuation and discontinuation of antiangiogenic drugs are often
rendered based on therapeutic efﬁcacy by monitoring primary
tumour changes. The consequences of discontinuation of treat-
ment in facilitating cancer metastasis in other organs are
completely overlooked. Another challenging issue in relation to
discontinuation of antiangiogenic therapy is the current drug
delivery scheduling. For treatment of cancer patients, bevacizumab
(once injection per month) and for subnitinib (4 week on and 2
week off) were systemically administrated in a disruptive
scheduling. Would these scheduling increase cancer metastasis
through mechanisms described in our study? Although there is no
deﬁnite answer to this important clinical question, we can
reasonably speculate that it is highly plausible for current
antiangiogenic therapy scheduling to promote cancer metastasis.
What is optimized scheduling of antiangiogenic therapy for human
cancer patients? One possible solution would be to administrate
low-dose of antiangiogenic drugs as non-stop maintenance
therapy. If so, survival beneﬁts of antiangiogenic therapy could
be potentially improved in cancer patients. This interesting issue
warrants clinical validation.
Our present data provide new mechanistic insights on
withdrawal of antiangiogenic drug-induced liver cancer metas-
tasis. As bevacizumab is used as the ﬁrst-line therapy for
treatment of CRCs that often metastasize to liver tissues, our
ﬁndings are clinically relevant. In support of our results, clinical
trial data using prolonged and sustained antiangiogenic regimens
demonstrate beneﬁcial improvement compared with short-term
therapy. Based on these preclinical and clinical ﬁndings, we
reasonably propose non-stop antiangiogenic therapy should
be considered in cancer patients. Rigorous clinical trials
by monitoring cancer metastasis after discontinuation of
antiangiogenic therapy warrant further consideration.
Methods
Cell culture. VEGF-null 528ras tumour cell line was kindly provided by Dr Janusz
Rak at the McGill University, Montreal, Canada; Mouse MC38 colon cancer cell line
was kindly provided by Dr Rube´n Herna´ndez at the Gene Therapy Unit, Center for
Applied Medical Research, University of Navarra, Pamplona, Navarra, Spain; and
Hepa 1–6 cell line was kindly provided by Dr Takuji Torimura at the Division of
Gastroenterology, Department of Medicine, Kurume University School of Medicine,
Kurume, Fukuoka, Japan. VEGF-null 528ras ﬁbrosarcoma, MC38 colon cancer and
HCC Hepa 1–6 cells were cultured in DMEM (HyClone; Cat. No. SH30243.01)
supplemented with 10% (vol/vol) heat-inactivated FBS (HyClone; Cat. No.
SH30160.03), 100Uml 1 penicillin, and 100mgml 1 streptomycin (HyClone; Cat.
No. SV30010). MC38, Hepa 1-6 and 528ras cells were stably transfected with luci-
ferase or Egfp reporter genes, followed by sorting with FACS. All the cell lines were
not authenticated after purchase or transferred from other laboratories. We routinely
tested mycoplasma contaminations in all our cell lines and they were negative.
Animals. All animal studies were approved by the Animal Ethics Committee of
Northern Stockholm. Female C57Bl/6 mice at age 6–8 weeks were provided by the
MTC animal facility of the Karolinska Institutet, Sweden, and caged in a group of
10 or fewer mice per cage. Vegf ﬂox/ﬂox mice in C57Bl/6 background were kindly
provided by Dr Napoleone Ferrara from Genentech Inc., San Francisco, USA; and
immunodeﬁcient CB17/Icr-Prkdcscid/IcrCrl mice were purchased from the Charles
River Laboratories.
Orthotopic tumour and metastasis models. Before tumour implantation, mice
were anaesthetized with hypnorm-dormicum (Vetapharma, Leeds, UK) at 1:1 ratio.
For spleen tumour implantation, a left subcostal surgical incision was created and
1 106 tumour cells in 30 ml were injected into the exposed hemispleen of each
mouse. For liver portal vein tumour model, 1 106 tumour cells in 30ml were
injected into the portal vein of each mouse. For the orthotopic colon cancer
model, 1 106 MC38 colon cancer cells were injected into the caecum wall using a
33-gauge Hamilton syringe (Cat. No. 7803-05, Hamilton). For the liver
orthotopic HCC model, 2 106 HCC Hepa 1–6 cells in 30ml were injected into the
left lobe of each mouse liver. Peritoneum and skin were surgically sutured with a
4-0 running stitch (Cat. No. V422H, Ethicon) and mice were simultaneously
treated with a pain killer (Temgesic (Reckitt Benckiser, Berkshire, UK),
0.1mg kg 1, twice per day) for 2 consecutive days after operation. In some
experiments, primary tumours and spleens were surgically removed under an
anesthesthetic condition. Approximately 2–3 weeks after tumour implantation,
hepatic metastases were detected using an in vivo imaging system. Between 2 and 4
weeks after tumour implantation, mice were killed and liver or lung tissues
were analysed for visible tumour nodules and histologically examined. In all
experiments, 6–12 mice were used in each group.
Anti-VEGF treatment. A humanized rabbit anti-mouse monoclonal VEGF-speciﬁc
neutralizing antibody (BD0801) was kindly provided by the Simcere Pharmaceutical
Company (Nanjing, Jiangsu, China) 36,50. A non-immune rabbit IgG isotype
(Cat. No. 10500C, Invitrogen) was used as a control vehicle. Sunitinib was purchased
from the LC laboratory (Cat. No. S-8803, LC Laboratories) and was diluted with
drinking water. Anti-VEGF neutralizing antibody at the dose of 5mg per kg was
intraperitoneally injected twice per week into each mouse. Sunitinib was orally
administrated once daily at the dose of 100mg kg 1. Tissue samples were collected
at days 0, 3, and 7 and off-drug at days 2, 4, 6, 8, 10, 12, 14 and 18. For scanning
electron microscopy analysis, additional time points including off-drug days 21, 28
and 42 were used. For cancer metastasis models, similar treatment schedules were
used before or after tumour implantation. At day 6 off-drug, animals of anti-VEGF-
treated and vehicle-treated groups were examined. For sunitinib-treated and vehicle-
treated groups, animals at day 2 off-drug were examined.
Immunoblot. Fresh liver tissues were immediately lyzed in the presence of
proteinase and phosphatase inhibitors (Cat. No. P8340, Sigma; 1:100;
Cat. No. 5870, Cell Signaling; 1:100). An equal amount of protein samples from
each group was separated by a 4–12% Bis-Tris NuPAGE gradient gel, followed by
transferring onto a nitrocellulose membrane. Membranes were probed overnight at
4 C with a rabbit anti-phospho-VEGFR2 antibody (Cat. No. 2471, Cell Signaling;
1:1,000), a rabbit anti-total-VEGFR2 antibody (Cat. No. 2479, Cell Signaling;
1:1,000), and a mouse anti-b-actin antibody (Cat. No. 3700, Cell Signaling; 1:1,000)
in PBS with 5% BSA containing 0.1% Tween 20. Membranes were incubated at
room temperature for 1 h with a donkey anti-rabbit IgG antibody (Cat. No.
926-68073, IRDye 680RD; LI-COR; 1:1,5000) and a donkey anti-mouse IgG
antibody (Cat. No. 926-32212, IRDye 800CW; LI-COR; 1:1,5000). Protein bands
were visualized and quantiﬁed using the ODYSSEY CLx (LI-COR) detection
system at 700 and 800 nm wavelengths.
RT-PCR and qPCR. PCR with reverse transcription (RT–PCR) and quantitative
PCR (qPCR) were performed according to standard protocols51–53. In brief, total
RNA samples were prepared by a GeneJet RNA Puriﬁcation Kit (Cat. No. K0731,
Thermo Scientiﬁc, MA, USA), and cDNA was synthesized using a RevertAid H
minus First Strand cDNA Synthesis Kit (Cat. No. K1632, Thermo Scientiﬁc,
MA, USA). RT-PCR was performed using a DreamTaq Green PCR Master Mix Kit
(Cat. No. K1082, Thermo Scientiﬁc, MA, USA) and 2720 PCR machine
(Applied Biosystems, CA, USA). qPCR was performed using a Power SYBR Green
Master Mix Kit (Cat. No. 4367659, Applied Biosystems, CA, USA) and a Step One
Plus real-time PCR system (Applied Biosystems, CA, USA). The following
primers were used: mouse Gapdh forward: 50-CCAGCAAGGACACTGAGCAA-30
and mouse Gapdh reverse 50-GGGATGGAAATTGTGAGGGA-30 ; mouse
Hif1a forward: 50-GTCGGACAGCCTCACCAAACAG-30 and mouse Hif1a
reverse 50-TAGGTAGTGAGCCACCAGTGTCC-30 . Triplicate samples were
analysed in each group.
ELISA. Fifty milligrams of fresh liver or tumour tissue were homogenized in a
500 ml lysis buffer (Cat. No. C3228, Sigma) containing a cocktail of proteinase
inhibitors (Cat. No. P8340, Sigma) using an electronic homogenizer. For tumour
cells, 1 106 cells were lyzed with the same lysis buffer. Tissue homogenates and
lyzed cells were centrifuged at 10,000g for 15min and 50ml of supernatant from
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms12680 ARTICLE
NATURE COMMUNICATIONS | 7:12680 | DOI: 10.1038/ncomms12680 |www.nature.com/naturecommunications 11
each sample were analysed using an enzyme-linked immunosorbent assay (ELISA)
kit detecting mouse VEGF (Cat. No. MMV00, R&D Systems Inc.) according to the
manufacturer´s instruction. For detection of non-bound free VEGF, tissue
supernatants were pre-treated with Protein A/G Sepharose beads (Cat. No. sc-2003,
Santa Cruz) to remove VEGF-A that bound to the neutralizing antibody. The
antibody-free tissue samples were subsequently used for the VEGF-ELISA detection.
Immunohistochemistry and whole-mount staining. Parafﬁn-embedded tissues
were cut in 5-mm-thickness, mounted onto glass slides, baked for one hour at 60 C
deparafﬁnized in Tissue-Clear (Cat. No. 1466, Sakura), and sequentially rehydrated
in 99%, 95% and 70% ethanol. Tissue slides were counterstained Haematoxylin and
Eosin before dehydration with 95 and 99% ethanol and were mounted with
PERTEX (Cat. No. 00801, HistoLab). Stained tissues were analysed under a light
microscope (Nikon Eclipse TS100). Whole-mount staining was performed using
standard protocol54–57. Brieﬂy, small pieces of tissues were cut into thin slices and
ﬁxed in 4% PFA overnight, followed by treatment with proteinase K (20 mgml 1).
Tissues were incubated overnight at 4 C with primary antibodies: a goat anti-
mouse CD31 antibody (Cat. No. AF3628, R&D); a rabbit anti-mouse VE-cadherin
antibody (Cat. No. ab33168, Abcam); a rabbit anti-mouse Fibronectin antibody
(Cat. No. ab23750, Abcam); a rabbit anti-mouse Collagen IV antibody (Cat. No.
ab19808, Abcam); a rabbit anti-mouse Laminin antibody (Cat. No. ab30320,
Abcam); a rabbit anti-mouse NG2 antibody (Cat. No. MAB5384, Millipore); and a
rabbit anti-mouse GFP antibody (Cat. No. A11122, Invitrogen). After rigorous
washing, tissue samples were further stained for 2 h at room temperature with
secondary antibodies to recognize their respective primary antibodies: a donkey
anti-goat Alexa 555 antibody (Cat. No. A21432, Invitrogen); a donkey anti-goat
Alexa 488 antibody (Cat. No. A11055, Invitrogen); a donkey anti-goat Alexa 647
antibody (Cat. No. A21447, Invitrogen); and a donkey anti-rabbit Alexa 555
antibody (Cat. No. A31572, Invitrogen). After thorough washing, slides were
mounted and examined under a confocal microscope (Zeiss Confocal LSM510
Microscope). Three-dimensional images of each tissue sample were projected and
quantitative analyses from at least eight random different tissue sections were
performed using an Adobe Photoshop CS software programme.
Blood perfusion and vascular permeability. At different time points after
treatment, each mouse was anaesthetized and i.v. injected with 100 ml of
2,000-kDa-lysinated ﬂuorescein-labelled dextran (Cat. No. D7139, Invitrogen)37.
Animals were killed 5min after dextran injection, and tissues were dissected
and immediately ﬁxed with 4% PFA at 4 C. For permeability assay, 100ml of
70-kDa-lysinated ﬂuorescein-labelled dextran (Cat. No. D1818, Invitrogen) was i.v.
injected into each mouse. Animals were killed 15min after dextran injection. Liver
tissues were carefully dissected, whole-mount stained and examined by confocal
microscopy.
Scanning electron microscopy. At different time points after treatment, animals
were killed and immediately ﬁxed by vascular perfusion with 2.5% (vol/vol)
glutaraldehyde plus 1% PFA in 0.1M phosphate buffer (pH 7.4). Liver tissues were
dissected and further ﬁxed with the same ﬁxative. After rinsing with distilled water,
samples were dehydrated with a stepwise ethanol gradient and placed in acetone.
Specimens were then dried using a critical point dryer (Balzer, CPD 010,
Lichtenstein) with carbon dioxide. After drying, specimens were mounted on an
aluminium stub and coated with Platinum (Bal-Tec SCD 005). Tissue specimens
were analysed under an Ultra 55 ﬁeld emission scanning electron microscope (Zeiss,
Oberkochen, Germany) at 3 kV (ref. 58).
Vascular casting. Vascular casting was performed according to our standard
protocol59. In brief, mice were anaesthetized with hypnorm-dormicum
(Vetapharma, Leeds, UK) at 1:1 ratio. Mice were surgically operated to expose the
aorta arch. A closed i.v. catheter system (Cat. No. 383532, BD Biosciences)
connected to a reservoir of physiological saline (0.9% NaCl) was inserted into the
aorta. Mice were ﬂushed with 10–20ml Ringer’s buffer, and subsequently injected
with a 10–20ml mixture solution containing PU4ii resin (VasQTec, Zurich,
Switzerland), ethyl methyl ketone (10:4 dilution; Cat. No. 1060141000, Millipore)
and hardener (VasQTec, Zurich, Switzerland). Mice were kept overnight at room
temperature to allow resin polymerization. Hepatic tissues were dissected and
treated with one or more changes of 20% NaOH. Casts were rinsed ﬁrst in distilled
water, then in 96% ethanol and dried in a desiccator for 48 h. Relevant pieces of
cast were dissected and mounted onto aluminium stubs using double-sided carbon
tape. Preparations were sputter coated with 4 nm gold on a low vacuum coater (EM
ACE200, Leica Microsystems GmbH, Wetzlar, Germany), and viewed in a XL30
scanning electron microscope (FEI, OR, USA).
Adenovirus delivery. Adenovirus-Cre was purchased from Vector Biolabs
(Cat. No.1045, Vector Biolabs). Adenovirus stocks were prepared according to our
standard protocol54. Each mouse was i.v. injected on every 5th day with 100 ml of
adenovirus containing 1 109 PFU particles.
In vivo bioluminescent imaging. Primary and metastatic tumour masses were
monitored with an IVIS Spectrum CT system (PerkinElmer). Brieﬂy,
tumour-bearing mice were injected with D-luciferin (150mg kg 1, PerkinElmer)
and luminescence-positive signals were detected by IVIS Spectrum CT system after
10–20min injection (PerkinElmer). For some experiments, dissected liver tissues
were subjected for imaging analysis. Metastatic lesions were further validated by
H&E histological analysis and ﬂuorescent microscopy.
Statistical analysis. For quantitative analysis, randomized micrographs from at
least eight different ﬁelds were used. The Adobe Photoshop CS4 software
programme was used with a colour range tool and a count tool to detect positive
areas and numbers. Sample sizes were carefully chosen for each experiment based
on pilot experiment examinations and sufﬁcient statistic powers. For all tumour
studies, at least six animals per group were used to ensure the adequate power.
Each experiment was repeated 2 times. Animals were excluded from the analysis if
they did not meet the pre-established criteria of the Karolinska Institute template.
In all animal experiments, experimental animals were randomly and blindly
divided into each group to receive various treatments. A standard two-tailed
Student’s t-test was used for all statistical analyses. All sample sizes were
appropriate for assumption of normal distribution and variance was similar
between compared groups. The statistical values of Po0.05, Po0.01 and Po0.001
were considered statistically signiﬁcant. Values of mean determinants are presented
as±s.e.m. The authors declare that the data supporting the ﬁndings of this study
are available within the article and its Supplementary Information ﬁles.
Data availability. The authors declare that the data supporting the ﬁndings of this
study are available within the article and its Supplementary Information ﬁles.
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